Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) was down 7.6% on Friday . The company traded as low as $47.67 and last traded at $48.00. Approximately 4,368,169 shares were traded during mid-day trading, a decline of 16% from the average daily volume of 5,195,375 shares. The stock had previously closed at $51.97.
Wall Street Analyst Weigh In
Several research analysts have commented on TEM shares. Wolfe Research downgraded Tempus AI from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. William Blair reaffirmed a "market perform" rating on shares of Tempus AI in a research note on Tuesday, February 25th. TD Cowen reissued a "buy" rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. JPMorgan Chase & Co. downgraded shares of Tempus AI from an "overweight" rating to a "neutral" rating and boosted their price target for the stock from $50.00 to $55.00 in a research report on Tuesday, February 25th. Finally, Loop Capital decreased their price objective on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a research report on Tuesday, January 14th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, Tempus AI presently has a consensus rating of "Moderate Buy" and an average target price of $61.18.
View Our Latest Research Report on Tempus AI
Tempus AI Trading Up 0.9 %
The firm's fifty day moving average price is $58.38 and its two-hundred day moving average price is $51.56. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.
Insider Activity at Tempus AI
In related news, COO Ryan Fukushima sold 20,000 shares of Tempus AI stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $39.61, for a total value of $792,200.00. Following the completion of the sale, the chief operating officer now owns 982,442 shares of the company's stock, valued at approximately $38,914,527.62. This trade represents a 2.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jennifer A. Doudna sold 1,320 shares of the company's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $90.00, for a total transaction of $118,800.00. Following the transaction, the director now owns 36,011 shares in the company, valued at approximately $3,240,990. The trade was a 3.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,598,969 shares of company stock valued at $317,194,162 in the last three months.
Hedge Funds Weigh In On Tempus AI
Large investors have recently added to or reduced their stakes in the business. Operose Advisors LLC purchased a new stake in shares of Tempus AI in the fourth quarter worth approximately $25,000. Farther Finance Advisors LLC bought a new stake in Tempus AI during the fourth quarter worth $34,000. Prestige Wealth Management Group LLC raised its position in Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after buying an additional 965 shares during the last quarter. NewEdge Advisors LLC bought a new position in Tempus AI during the 4th quarter valued at $49,000. Finally, First Horizon Advisors Inc. boosted its holdings in Tempus AI by 207.9% during the 4th quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock worth $55,000 after acquiring an additional 1,108 shares during the last quarter. Institutional investors own 24.22% of the company's stock.
About Tempus AI
(
Get Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Further Reading
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
